Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IAG933 in Advanced Mesothelioma and Other Solid Tumors
NCT04857372Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of IAG933 in mesothelioma and solid tumor (4 arms), sponsored by Novartis. Primary endpoints: Number of patients with adverse events and serious adverse events at 3 years, Incidence of dose limiting toxicities at 1 year and 1 more. Started Oct 2021; status: active, not recruiting.
02
Drugs
IAG933
03
Conditions
mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT04857372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857372.